
Year End Message from our CEO
News and BlogDear AxoSim Supporters, This year has been one of amazing progress both for AxoSim and for our entire industry. We have seen […]
Read MoreAxoSim empowers advancements in human neuroscience and accelerates the drug development process through our NerveSim® and BrainSim® drug discovery platforms
Learn MoreOur technology enables researchers to predict human outcomes in the lab. We deliver accurate preclinical testing to help develop safer, more effective drugs.
Almost 90% of drugs that look promising in animal models fail when tested in humans, driving up the average cost and time of new drug development to $2.6 billion and 10 years or more. We deliver predictive human data in just weeks and at a fraction of the cost of in vivo studies.
Achieve the predictive readouts critical to your R&D success. We deliver clinically-relevant functional and structural metrics to improve success rates.
AxoSim's NerveSim® platform facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.
BrainSim® is a high quality 3D miniature brain organoid designed to serve as a human-relevant model in preclinical drug discovery.
Dear AxoSim Supporters, This year has been one of amazing progress both for AxoSim and for our entire industry. We have seen […]
Read MoreThe AxoSim Team will be on the road for the Society of Neuroscience 2022 Annual Meeting in San Diego, CA. We are […]
Read MoreMeet AxoSim Research Scientist Lise Harbom, PhD Tell us about yourself. I attended Vanderbilt University for undergraduate studies where I double majored […]
Read MoreCheck out AxoSim CEO Lowry Curley PhD, and Obatala Sciences CEO Trivia Frazier’s, PhD, MBA, op-ed highlighting their experiences growing companies in Southeast Louisiana and how important funding […]
Read More